SCM Lifescience to in-license iPSCs-based diabetes drug from U.S. firm – Pulse by Maeil Business News Korea July 02, 2021, Seoul SCM Lifescience has agreed to in-license a diabetes drug using pancreatic beta cells derived from induced pluripotent stem cells (iPSCs) from San Diego-based Allele Biotechnology and Pharmaceuticals, the South Korean stem cell therapy developer…
DetailsAllele Discloses How its Highly Efficient iPSC Culturing is Conducted Under cGMP July 14, 2020 06:00 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–In their latest paper published in the online prepublication by the peer-reviewed journal Current Protocols, scientists and cGMP operation managers at Allele Biotechnology present a series of step-by-step protocols for manufacturers of iPSC (induced…
DetailsAllele Biotech’s cGMP iPSCs Used as Packaging Factories for mRNA January 02, 2021 San Diego, CA January 2, 2021 (Updated from an earlier BusinessWire news announcement)– Allele Biotechnology and Pharmaceuticals, Inc. (Allele) has leveraged mRNA technology for over a decade to create cGMP-grade induced pluripotent stem cell (iPSC) lines for regenerative medicine and oncology applications.…
Details